Key facts
- Prazer Therapeutics’s last known valuation is $57.3M (Nov 2020).
- It has raised $35.9M; the latest was Later Stage VC ($20.0M) in Mar 2025.
- Notable investors include Tech Incubator Program for Startup, Smilegate Investment, Mirae Asset Capital, STIC Ventures, Kiwoom Investment — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Prazer Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Prazer Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Prazer Therapeutics
Operator of a biotechnology company intended to develop novel therapeutics to treat a variety of refractory diseases. The company is focused on developing therapeutics for the treatment of neurodegenerative diseases and refractory inflammatory diseases using next-generation protein degradation technology, enabling the healthcare industry to focus on the advancement of novel drugs in areas of unmet medical need.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 27
- Website
- prazertx.com/
- Ownership
- Privately Held (backing)
Prazer Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prazer Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prazer Therapeutics in its N-PORT filings yet. We sweep new filings monthly.